Your browser doesn't support javascript.
loading
Chemically Programmable and Switchable CAR-T Therapy.
Qi, Junpeng; Tsuji, Kohei; Hymel, David; Burke, Terrence R; Hudecek, Michael; Rader, Christoph; Peng, Haiyong.
Afiliación
  • Qi J; Department of Immunology and Microbiology, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL, 33458, USA.
  • Tsuji K; Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 376 Boyles Street, Frederick, MD, 21702, USA.
  • Hymel D; Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo, 101-0062, Japan.
  • Burke TR; Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 376 Boyles Street, Frederick, MD, 21702, USA.
  • Hudecek M; Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 376 Boyles Street, Frederick, MD, 21702, USA.
  • Rader C; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Oberdürrbacherstrasse 6, 97080, Würzburg, Germany.
  • Peng H; Department of Immunology and Microbiology, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL, 33458, USA.
Angew Chem Int Ed Engl ; 59(29): 12178-12185, 2020 07 13.
Article en En | MEDLINE | ID: mdl-32329959
ABSTRACT
Although macromolecules on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small molecules and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility. Compared to antibodies, however, small molecules are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inability to communicate with the immune system. Presented herein is a method that endows small molecules with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts). It is based on a CAR-T platform that uses a chemically programmed antibody fragment (cp-Fab) as on/off switch. In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in vivo.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos Límite: Animals / Humans Idioma: En Revista: Angew Chem Int Ed Engl Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos Límite: Animals / Humans Idioma: En Revista: Angew Chem Int Ed Engl Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos